Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials

Cancer Treatment Reviews

Volumn 23, Issue 1, 1997, Pages 35-61

  Newlands, E S ^a   Stevens, M F G ^b   Wedge, S R ^a   Wheelhouse, R T ^c   Brock, C ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GRANISETRON; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONDANSETRON; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CHEMICAL REACTION; CLINICAL TRIAL; CYTOTOXICITY; DNA METHYLATION; DNA REPAIR; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG SYNTHESIS; EXCISION REPAIR; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKOPENIA; LUNG CANCER; MELANOMA; META ANALYSIS; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PH; POSITRON EMISSION TOMOGRAPHY; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0030993717     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90019-0     Document Type: Article

References (106)

1. Stevens, M. F. G. & Newlands, E. S. (1993) From triazines and triazenes to temozolomide. Eur. J. Cancer 29A: 1045-1047.
2. Mizuno, N. S. & Decker, R. W. (1976) Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347). Biochem. Pharmacol. 25: 2643-2647.
3. Stevens, M. F. G., Hickman, J. A., Stone, R. et al. (1984) Antitumor Imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent. J. Medicin. Chem. 27: 196-201.
4. Hickman, J. A., Stevens, M. F. G., Gibson, N. W. et al. (1985) Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res. 45: 3008-3013.
5. Newlands, E. S., Blackledge, G., Slack, J. A. et al. (1985) Phase I clinical trial of mitozolomide (CCRG 81010; M&B 39565; NSC 353451). Cancer Treat. Rep. 69: 801-805.
6. Gibson, N. W., Hickman, J. A., & Erickson, L. C. (1984) DNA cross-linking and cytotoxicity in normal and transform cells treated with 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 44: 1772-1775.
7. Stevens, M. F. G., Hickman, J. A., Langdon, S. P. et al. (1987) Antitumor activity and pharmacokinetics of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47: 5846-5852.
8. Newlands, E. S., Blackledge, G. R. P., Slack, J. A. et al. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65: 287-291.
9. Ege, G. & Gilbert, K. (1979) [7+2]- and [11+2]-cycloaddition reactions of diazoazoles with isocyanates to azolo[5,1-d][1,2,3,5]tetrazine-4-ones. Tetrahedron Lett. 4253-4256.
10. Lunt, E., Newton, C. G., Smith, C. et al. (1987) Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones. J. Medicin. Chem. 30: 357-366.
11. Stevens, M. F. G. (1987) Second-generation azolotetrazinones. In Harrap, K. R. & Connors, T. A., eds, New Avenues in Developmental Cancer Chemotherapy, Volume 8. Bristol-Myers Cancer Symposium. Orlando: Academic Press, pp. 335-354.
12. Wang, Y-F., Stevens, M. F. G. & Thomson, W. (1994) Alternative syntheses of the antitumour drug temozolomide avoiding the use of methyl isocyanate. J. Chem. Soc., Chem. Commun. 1687-1688.
13. Wang, Y-F., Stevens, M. F. G., Thomson, W. T. & Shutts, B. P. (1995) Antitumour imidazotetrazines. Part 33. New syntheses of the antitumour drug temozolomide using 'masked' methyl isocyanates. J. Chem. Soc., Perkin Trans. 1: 2783-2787.
14. 15N) magnetic resonance investigation of temozolomide and mitozolomide. J. Chem. Soc., Perkin Trans. 1: 249-252.
15. 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. Magn. Reson. Med. 34: 338-342.
16. 11C-methyl] methyl isocyanate and application with microwave heating to labelling the novel anticancer agent temozolomide. J. Label. Comp. Radiopharm. 30: 100-102.
17. Slack, J. A. & Goddard, C. (1985) Antitumour imidazotetrazines. VII. Quantitative analysis of mitozolomide in biological fluids by high-performance liquid chromatography. J. Chromatog. 337: 178-181.
18. Threadgill, M. D. (1990) The chemistry of azolotetrazinones. In: Wilman, D. E. V., ed., The Chemistry of Antitumour Agents. Glasgow: Blackie and Son, pp. 187-201.
19. Baig, G. U. & Stevens M. F. G. (1987) Antitumour imidazotetrazines. Part 12. Reactions of mitozolomide and its 3-alkyl congeners with oxygen, nitrogen, halogen and carbon nucleophiles. J. Chem. Soc., Perkin Trans. 1; 665-670.
20. Horspool, K. R., Stevens, M. F. G., Newton, C. G. et al. (1990) Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative mitozolomide and its utility in the preparation of active antitumor agents. J Medicin. Chem. 30: 1393-1399.
21. Wheelhouse, R. T. & Stevens, M. F. G. (1993) Decomposition of the antitumour drug temozolomide in deuteriated phosphate buffer: methyl group transfer is accompanied by deuterium exchange. J. Chem. Soc., Chem. Commun. 1177-1178.
22. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H. & Slack, J. A. (1994) NMR and molecular modelling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051.
23. Tsang, L. L. H., Farmer, P. B., Gescher, A. & Slack, J. A. (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother. Pharmacol. 26: 429-436.
24. Vaupel, P., Kallinowski, F. & Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49: 6449-6465.
25. Clark, A. S., Stevens, M. F. G., Sansom, C. E. & Schwalbe, C. H. (1990) Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. Anti-Cancer Drug Design 5: 63-68.
26. Lowe, P. R., Sansom, C. E., Schwalbe, C. H., Stevens, M. F. G. & Clarke, A. S. (1992) Antitumour imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomidel) and structural comparisons with the related drugs mitozolomide and DTIC. J. Medicin. Chem. 30: 3377-3382.
27. Clark, A. S., Deans, B., Stevens, M. F. G. et al. (1995) Antitumour imidazotetrazines and related bicyclic heterocycles to probe the mode of action of the antitumour drug temozolomide. J. Medicin. Chem. 38: 1493-1504.
28. Bull, V. L. (1988) Studies on the Mode of Cytotoxicity of Imidazotetrazinones. Ph.D. Thesis, Aston University.
29. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol. 36: 457-462.
30. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer 67: 1299-1302.
31. 6-benzylguanine: a comparative study in vitro. Br. J. Cancer 73: 482-490.
32. 6-substituted guanine-induced mutagenesis of ras oncogenes. Proc. Natl. Acad. Sci. USA 86: 8650-8654.
33. Brennand, J. & Margison, G. P. (1986) Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harbouring the Escherichia coli alkyltransferase gene. Proc. Natl. Acad. Sci. USA 83: 6292-6296.
34. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129.
35. Catapano, C. V., Broggini, M., Erba, E. et al. (1987) In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res. 47: 4884-4889.
36. 6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 3: 401-405.
37. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA 87: 5368-5372.
38. 6-Methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res 11: 115-122.
39. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 32: 59-63.
40. Fishel, R., Lescoe, M. K., Rao, M. R. S. et al. (1993) The human mutator gene hololog MSH2 and its association with hereditary nonpolyposis cancer. Cell 75: 1027-1038.
41. Drummond, J. T., Li, G. M., Longley, M. J. & Modrich, P. (1995) Isolation of an hMSH2-p 160 heterodimer that restores DNA mismatch repair to tumor cells. Science 268: 1909-1912.
42. Palombo, F., Gallinari, P., Iaccarino, I. et al. (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268: 1912-1914.
43. Li, G-M & Modrich, P. (1995) Restoration of mismatch repair to nuclear extracts of H6 colorectal tumour cells by a heterodimer of human MutL homologs. Proc. Natl. Acad. Sci. USA 92: 1950-1954.
44. 6-Methylguanine residues elicit DNA repair synthesis by human cell extracts. J. Biol. Chem. 268: 15878-15886.
45. Plant, J. E. & Roberts, J. J. (1971) Extension of the pre-DNA synthetic phase of the cell cycle as a consequence of DNA alkylation in Chinese hamster cells: a possible mechanism of DNA repair. Chemico-Biol. Interact. 3: 343-351.
46. 6-Methylguanine in DNA inhibits replication in vitro by human cell extracts. Biochemistry 32: 13664-13672.
47. Aaltonen, L. A., Peltomäki, P., Leach, F. S. et al. (1993) Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC) 260: 812-816.
48. Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D. & Perucho, M. (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colon carcinogenesis. Nature (Lond.) 363: 558-561.
49. 6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer 74: 1030-1036.
50. Liu, L., Markowitz, S., Willson, J. K. V. & Gerson, S. L. (1996) Mismatch repair mutator phenotype confers resistance to temozolomide in human colon cancer cell lines. Proc. Amer. Assoc. Cancer Res. 37: 365 (A2491).
51. Dianov, G. & Lindahl, T. (1994) Reconstitution of the DNA base excision-repair pathway. Curr. Biol. 4: 1069-1076.
52. Bailly, V. & Verly, W. G. (1988) Possible roles of β-elimination and δ-elimination reactions in the repair of DNA containing AP (apurinic/apyrimidinic) sites in mammalian cells. Biochem. J. 253: 553-559.
53. 8-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis 15: 533-537.
54. Deans, B. & Tisdale, M. J. (1992) Antitumour imidazotetrazines-XXVIII. 3-Methyladenine-DNA glycosylase activity in cell lines sensitive and resistant to temozolomide. Cancer Lett. 63: 151-157.
55. Tisdale, M. J. (1985) Antitumour imidazotetrazines-XI: Effect of 8-carbamoyl-3-methylimidazo[5, 1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M & B 39831; NSC 362856] on poly(ADP-ribose) metabolism. Br. J. Cancer 52: 789-792.
56. Satoh, M. S. & Lindahl, T. (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature (Lond.) 356: 356-358.
57. Rankin, P. W., Jacobson, E. L., Benjamin, R. C., Moss, J. & Jacobson, M. K. (1989) Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J. Biol. Chem. 264: 4312-4317.
58. Boulton, S., Pemberton, L. C., Porteous, J. K. et al. (1995) Potentiation of temozolomide-induced cytotoxicity. A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer 72: 849-856.
59. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311.
60. Nosseri, C., Coppola, S. & Ghibelli, L. (1994) Possible involvement of poly(ADP-ribose) polymerase in triggering stress-induced apoptosis. Exp. Cell. Res. 212: 367-373.
61. Tisdale, M. J. (1985) Induction of haemoglobin synthesis in the human leukaemia cell line K562 by monomethyltriazenes and imidazotetrazinones. Biochem. Pharmacol. 34: 2077-2082.
62. Tisdale, M. J. (1986) Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5, 1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562. Biochem. Pharm. 35: 311-316.
63. Tisdale, M. J. (1989) Antitumour imidazotetrazines-XVII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones. Biochem. Pharm. 1097-1101.
64. 6-methylguanine residues. J. Biol. Chem. 266: 7985-7987.
65. Bull, V. L. & Tisdale, M. J. (1987) Antitumour imidazotetrazines-XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem. Pharmacol. 36: 3215-3220.
66. Dive, C., Workman, P. & Watson, J. V. (1989) Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry. Cancer Chemother. Pharmacol. 25: 149-155.
67. Brindley, C. J., Antoniw, P. & Newlands, E. S. (1986) Plasma and tissue disposition of mitozomide in mice. Br. J. Cancer 53: 91-97.
68. Carter, C. A., Waud, W. R. & Plowman, J. (1994) Responses of human melanoma, ovarian, and coloc tumour xenografts in nude mice to oral temozolomide. Proc. Amer. Assoc. Cancer Res. 35: 297 (A1769).
69. Plowman, J., Waud, W. R., Koutsoukos, A. D., Rubinstein, L. V., Moore, T. D. & Grever, M. R. (1994) Pre-clinical antitumor activity of temozolomide in mice; efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54: 3793-3799.
70. Friedman, H. S., Dolan, M. E., Pegg, A. E. et al. (1995) Activity of temozolomide in the treatment of central nervous system tumour xenografts. Cancer Res. 55: 2853-2857.
71. Steward, D. (1989) The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev. 16: 129-160.
72. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer 73; 1049-1052.
73. 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother. Pharmacol. (in press).
74. 6-benzylguanine. Biochem. J. 298: 231-235.
75. 6-benzylguanine using a transgenic model. Cancer Res. 56: 1880-1885.
76. Waud, W. R., Rubinstein, L. V., Kalyandrug, S., Plowman, J. & Alley, M. C. (1996) In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide. Proc. Amer. Assoc. Cancer Res. 37: 292 (A1988).
77. Tentori, L., Leonetti, C. & Aquino, A. (1995) Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of alpha-6 integrin phosphorylation. Eur. J. Cancer 31A: 746-754.
78. Pero, R. W., Roush, G. C., Markowitz, M. M. & Miller, D. G. (1990) Oxidative stress, DNA repair, and cancer susceptibility. Cancer Detect. Prev. 14: 555-561.
79. 6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem. Pharmacol. 46: 285-290.
80. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 51: 3367-3372.
81. 6-Alkylguanine-DNA alkyltransferase activity in myeloid cells. J. Clin. Invest. 76: 2106-2114.
82. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol. 23: 112-116.
83. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat. Res. 145: 1-16.
84. Wedge, S. R., Porteous, J. K. & Newlands, E. S. (1996) Temozolomide: a candidate for combination with loco-regional radiotherapy? Br. J. Cancer, 73 (Suppl. XXVI): 43 (P67).
85. Heriat, P., Rougier, P., Oliveira, J. et al. (1988) Phase II study of mitozolomide (M&B39565) in colorectal and breast cancer. Invest. New Drugs 6: 323.
86. Blackledge, G., Roberts, J. T., Kaye, S. B. et al. (1989) Phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Eur. J. Cancer Clin. Oncol. 25: 391.
87. Harding, M., Northcott, D., Smyth, J., Stuart, N. S. A., Green, J. A. & Newlands, E. S. (1988) Short communication in: Phase II evaluation of mitozolomide in ovarian cancer. Br. J. Cancer 57: 113.
88. Neijt, J. P., Van Der Burg, M. E., Guastalla, J. P., George, M., Vermorken, J. B. & Rotmentsz, N. (1987) Mitozolomide in patients with advanced ovarian carcinoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group.: Proc., ECCO-4. Fourth Eur. Conf. Clin. Oncol. Cancer Nursing; Federation of European Cancer Studies, 214 (Abstract).
89. Van Oosterom, A. T., Stoter, G., Bono, A. V. et al. (1989) Mitozolomide in advanced renal cancer: a Phase II study in previously untreated patients from the EORTC Genitourinary Tract Cancer Cooperative Group. Eur. J. Cancer Clin. Oncol. 25: 1249.
90. Gunderson, S., Aamdal, S. & Fodstad, O. (1987) Mitozolomide (NSC35451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br. J. Cancer 55: 433.
91. Schornagel, J. H., Simonetti, G. & McVie, J. G. (1986) Phase I study of mitozolomide (NSC 54351) using a daily x 5 schedule. Proc. Fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy (Abstract).
92. Bleehen, N. M., Newlands, E. S., Lee, S. M. et al. (1995) Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13: 910-913.
93. Woll, P. J., Crowther, D., Johnson, P. W. M. et al. (1995) Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br. J. Cancer 72: 183-184.
94. O'Reilly, S. M., Newlands, E. S., Glaser, M. G. et al. (1993) Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 29A: 940-942.
95. Newlands, E. S., O'Reilly, S. M., Glaser, M. G. et al. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32: 2236-2241.
96. Newlands, E. S., Rustin, G. J. S., Evans, H., Wedge, S. R. & Brampton, M. H. (1996) Phase I trial of oral Temozolomide administered over 6 and 7 weeks. Proc. Ninth NCI-EORTC Symposium on New Drugs in Cancer Therapy 345 (Abstract).
97. Osaba, D., Aaronson, N. K., Muller, M. et al. (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Research 5: 139-150.
98. Price, P. & Jones, T. on behalf of the EC PET Oncology Concerted Action and the EORTC PET Study Group (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur. J. Cancer 31A: 1924-1927.
99. Hajnal, J. V., Saeed, N., Soar, E. J. et al. (1995) A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J. Comp. Assist. Tomog. 19: 289-296.
100. Hajnal, J. V., Saeed, N., Oatridge, A., Williams, E. J., Young, I. R. & Bydder, G. M. (1995) Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images. J. Comp. Assist. Tomog. 19: 667-691.
101. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Clinical Pharmacology. Proc. Am. Soc. Soc. Clin. Oncol. 15: 366 (Abstract).
102. Pearson, A. D. J., Estlin, E. J., Lashford, L. et al. (1996) Phase I study of temozolomide in paediatric patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 15: 1564 (Abstract).
103. O'Reilly, S. M., Harte, R. J. A., Newlands, E. S. et al. (1995) Early changes in tumour glucose metabolism may predict and quantify response of gliomas to chemotherapy. A Phase II study using temozolomide. Proc. Am. Soc. Clin. Oncol. 14: 1635 (Abstract).
104. Brock, C. S., Matthews, J. C., Brown, G. et al. (1996) The kinetic behaviour of temozolomide in man. Proc. Am. Soc. Clin. Oncol. 15: 1502 (Abstract).
105. 6-benzylguanine (BG) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 15: 355 (Abstract).
106. 6-alkylguanine DNA alkyltransferase directed DNA repair. Proc. Am. Soc. Clin. Oncol. 15: 362 (Abstract).